• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.比较阿扎胞苷治疗骨髓增生异常综合征患者中修订后的国际预后评分系统和法国预后评分系统的预后预测价值。
Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.
2
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.阿扎胞苷治疗第一个周期后血小板计数翻倍可预测骨髓增生异常综合征和少原始细胞急性髓系白血病患者的最终反应和生存情况，但并未增加修订版国际预后评分系统的预后效用。
Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4.
3
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.用于预测接受氮杂核苷治疗的高危骨髓增生异常综合征患者预后的风险分层工具比较
Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
4
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes.估算肾小球滤过率可独立预测高危骨髓增生异常综合征患者阿扎胞苷治疗的结局。来自希腊骨髓增生异常和低增生综合征国家登记处 536 例患者的结果。
Hematol Oncol. 2020 Oct;38(4):541-553. doi: 10.1002/hon.2756. Epub 2020 Jun 26.
5
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.修订版国际预后评分系统在骨髓增生异常综合征治疗患者中的验证。
Am J Hematol. 2013 Jul;88(7):566-70. doi: 10.1002/ajh.23454. Epub 2013 May 30.
6
Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study.低甲基化治疗对国际预后评分系统（IPSS）低危骨髓增生异常综合征患者的益处：一项回顾性多中心病例系列研究
Leuk Res. 2017 Sep;60:135-144. doi: 10.1016/j.leukres.2017.08.004. Epub 2017 Aug 15.
7
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.高危骨髓增生异常综合征和急性髓系白血病患者序贯使用阿扎胞苷和来那度胺：一项单臂1/2期研究。
Lancet Haematol. 2015 Jan;2(1):e12-20. doi: 10.1016/S2352-3026(14)00026-X. Epub 2014 Dec 22.
8
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine.单体核型可改善阿扎胞苷治疗的 MDS 和 AML 患者的 IPSS-R 分层。
Am J Hematol. 2013 Sep;88(9):780-3. doi: 10.1002/ajh.23509. Epub 2013 Jul 23.
9
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.骨髓中BCL2L10阳性细胞是骨髓增生异常综合征和急性髓系白血病中阿扎胞苷治疗结局的独立预后因素。
Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482.
10
The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.纤维蛋白原-白蛋白比值指数在接受阿扎胞苷治疗的伴骨髓增生异常相关改变的骨髓增生异常综合征和急性髓系白血病患者中的预后价值。
Ann Hematol. 2021 Apr;100(4):953-957. doi: 10.1007/s00277-021-04440-z. Epub 2021 Feb 1.

引用本文的文献

1
Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis.接受阿扎胞苷治疗的骨髓增生异常综合征患者的真实世界结局及预后因素——一项回顾性分析
Cancers (Basel). 2024 Mar 29;16(7):1333. doi: 10.3390/cancers16071333.
2
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.接受低甲基化药物治疗的骨髓增生异常综合征患者的提供者经验与临床结局的相关性。
Leuk Lymphoma. 2020 Feb;61(2):397-408. doi: 10.1080/10428194.2019.1663423. Epub 2019 Oct 1.
3
BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.骨髓中BCL2L10阳性细胞是骨髓增生异常综合征和急性髓系白血病中阿扎胞苷治疗结局的独立预后因素。
Oncotarget. 2017 Jul 18;8(29):47103-47109. doi: 10.18632/oncotarget.17482.
4
Improving Prognostic Modeling in Myelodysplastic Syndromes.改善骨髓增生异常综合征的预后模型
Curr Hematol Malig Rep. 2016 Dec;11(6):395-401. doi: 10.1007/s11899-016-0342-1.
5
Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.体细胞突变可预测骨髓增生异常综合征患者低甲基化治疗的疗效。
Oncotarget. 2016 Aug 23;7(34):55264-55275. doi: 10.18632/oncotarget.10526.
6
Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.用于预测接受氮杂核苷治疗的高危骨髓增生异常综合征患者预后的风险分层工具比较
Leukemia. 2016 Mar;30(3):649-57. doi: 10.1038/leu.2015.283. Epub 2015 Oct 14.
7
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?血液系统恶性肿瘤中分子检测对肿瘤专科医生的意义：进展能否兑现承诺？
Oncologist. 2015 Sep;20(9):1069-76. doi: 10.1634/theoncologist.2015-0067. Epub 2015 Jul 20.
8
MDS prognostic scoring systems – past, present, and future.骨髓增生异常综合征预后评分系统——过去、现在与未来。
Best Pract Res Clin Haematol. 2015 Mar;28(1):3-13. doi: 10.1016/j.beha.2014.11.001. Epub 2014 Nov 11.
9
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.TET2突变可预测骨髓增生异常综合征患者对去甲基化药物的反应。
Blood. 2014 Oct 23;124(17):2705-12. doi: 10.1182/blood-2014-06-582809. Epub 2014 Sep 15.
10
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.阿扎胞苷治疗第一个周期后血小板计数翻倍可预测骨髓增生异常综合征和少原始细胞急性髓系白血病患者的最终反应和生存情况，但并未增加修订版国际预后评分系统的预后效用。
Br J Haematol. 2014 Oct;167(1):62-8. doi: 10.1111/bjh.13008. Epub 2014 Jul 4.

本文引用的文献

1
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.阿扎胞苷联合或不联合恩替诺特治疗骨髓增生异常综合征和伴有骨髓增生异常相关改变的急性髓系白血病：美国白血病协作组试验 E1905 的结果。
J Clin Oncol. 2014 Apr 20;32(12):1242-8. doi: 10.1200/JCO.2013.50.3102. Epub 2014 Mar 24.
2
Validation of the Revised International Prognostic Scoring System for patients with myelodysplastic syndromes.修订版国际预后评分系统在骨髓增生异常综合征患者中的验证。
Acta Haematol. 2014;131(4):231-8. doi: 10.1159/000354840. Epub 2013 Dec 11.
3
Impact of the revised International Prognostic Scoring System on the outcome of patients with acute myeloid leukemia with or without antecedent myelodysplastic syndrome.修订后的国际预后评分系统对伴或不伴既往骨髓增生异常综合征的急性髓系白血病患者预后的影响
Leukemia. 2014 Mar;28(3):723-5. doi: 10.1038/leu.2013.356. Epub 2013 Nov 25.
4
Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.修订的国际预后评分系统（IPSS-R）在骨髓增生异常综合征患者中的验证：一项多中心研究。
Leuk Res. 2014 Jan;38(1):57-64. doi: 10.1016/j.leukres.2013.10.013. Epub 2013 Oct 26.
5
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.有风险，也有风险：骨髓增生异常综合征的最新临床预后风险分层模型。
Curr Hematol Malig Rep. 2013 Dec;8(4):351-60. doi: 10.1007/s11899-013-0172-3.
6
Current therapy of myelodysplastic syndromes.骨髓增生异常综合征的当前治疗。
Blood Rev. 2013 Sep;27(5):243-59. doi: 10.1016/j.blre.2013.07.003. Epub 2013 Jul 27.
7
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.修订后的国际预后评分系统（IPSS）比 IPSS 和世界卫生组织预后评分系统更能显著预测骨髓增生异常综合征的生存和白血病演变：意大利罗马米洛迪斯plasia 区域数据库的验证。
J Clin Oncol. 2013 Jul 20;31(21):2671-7. doi: 10.1200/JCO.2012.48.0764. Epub 2013 Jun 24.
8
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.修订版国际预后评分系统在骨髓增生异常综合征治疗患者中的验证。
Am J Hematol. 2013 Jul;88(7):566-70. doi: 10.1002/ajh.23454. Epub 2013 May 30.
9
The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.修订后的国际预后评分系统（IPSS）是评估接受阿扎胞苷治疗的骨髓增生异常综合征（MDS）患者预后的有力工具：法国骨髓增生异常综合征研究组（GFM）的经验。
Blood. 2012 Dec 13;120(25):5084-5. doi: 10.1182/blood-2012-09-453555.
10
Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?低甲基化剂能否为骨髓增生异常综合征的治愈疗法提供平台？
Best Pract Res Clin Haematol. 2012 Dec;25(4):443-51. doi: 10.1016/j.beha.2012.10.007. Epub 2012 Oct 25.

比较阿扎胞苷治疗骨髓增生异常综合征患者中修订后的国际预后评分系统和法国预后评分系统的预后预测价值。

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

机构信息

Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.

出版信息

Br J Haematol. 2014 Aug;166(3):352-9. doi: 10.1111/bjh.12884. Epub 2014 Apr 9.

DOI:10.1111/bjh.12884
PMID:24712482
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4299460/
Abstract

The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.

摘要

修订后的国际预后评分系统（IPSS-R）是在一组未经治疗的骨髓增生异常综合征（MDS）患者中开发的。最近有一项法国预后评分系统（FPSS）报告称，它可以识别接受阿扎胞苷治疗的高危 MDS 患者的生存差异。我们将 FPSS 和 IPSS-R 应用于 150 名先前随机分配至阿扎胞苷单药或阿扎胞苷联合恩替诺特（一种组蛋白去乙酰化酶抑制剂）治疗的患者。这两个评分都不能预测反应，但都能区分总生存期（OS）不同的患者（中位 OS，FPSS：9.7、14.7 和 25.3 个月，P = 0.018；IPSS-R：12.5、11.3、20.8 和 36 个月，P = 0.005）。统计分析表明，FPSS 不能改善阿扎胞苷治疗患者的 OS 预测。